Emergent BioSolutions signs $174 million arrangement to make AstraZeneca’s potential COVID-19 antibody
- Post By : Kumar Jeetendra
- Source: Reuters
- Date: 27 Jul,2020
AstraZeneca in June chose Emergent to assist make 300 million doses of its possible COVID-19 vaccine vowed to the USA.
AstraZeneca has signed manufacturing deals internationally to meet its goal of earning 2 billion gallons of this vaccine, for example with just two Bill Gates-backed ventures and a $1.2 billion deal with the US authorities.
The company’s vaccine, which is co-developed from the University of Oxford, is among the very first to move into mid-stage trials. There are no approved vaccines or treatments for COVID-19, the highly infectious respiratory illness brought on by the novel coronavirus.
The latest contract follows a $87 million deal in June where Emergent signed an agreement to become the growth partner for AstraZeneca’s COVID-19 vaccine candidate.
Activities under the agreement will likely be at Emergent’s Baltimore Bayview centre, the company said, which is a designated centre by the US Department of Health and Human Services for rapid manufacturing of large quantities of vaccines and treatments.